Limits...
Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results.

Morizane S, Iwamoto H, Yao A, Isoyama T, Sejima T, Takenaka A - Cent European J Urol (2012)

Bottom Line: The survival rates of patients with low serum albumin (<3.5 g/dL; P = 0.008), low hemoglobin (<10.1 mg/dL; P = 0.025), high CRP (>1.0 mg/dL; P = 0.001), and a positive pain score (P = 0.002) were significantly worse than those with better blood values and pain scores.Pretreatment serum CRP levels could be an accurate biomarker of the survival of patients with advanced UC before GC therapy.Although this is a preliminary study with a small sample size, these results seem to be very useful in clinical practice and our findings should be confirmed in a larger group of patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, Tottori, Japan.

ABSTRACT

Introduction: This study determines prognostic factors in patients with advanced urothelial cancer (UC) treated with gemcitabine-cisplatin or carboplatin (GC).

Material and methods: The clinical records of 30 patients with advanced UC treated with GC were retrospectively reviewed. Twenty-six patients (86.7%) had previously undergone other chemotherapies. Hematological parameters such as: neutrophil, lymphocyte and platelet counts; hemoglobin, C-reactive protein (CRP), and albumin levels; pain score; primary tumor site; tumor grade; type of platinum anti-cancer drug; and performance status before treatment were evaluated. Survival rates were calculated using the Kaplan-Meier method and analyzed using the log-rank test. Multivariate analysis was performed using a Cox proportional hazards model.

Results: The median cancer-specific survival (CSS) was 12.5 months. The overall response rate (ORR) was 30.0%. The survival rates of patients with low serum albumin (<3.5 g/dL; P = 0.008), low hemoglobin (<10.1 mg/dL; P = 0.025), high CRP (>1.0 mg/dL; P = 0.001), and a positive pain score (P = 0.002) were significantly worse than those with better blood values and pain scores. Multivariate analysis revealed serum CRP level as an independent prognostic indicator with a hazard ratio of 4.608 (95% confidence interval (CI) of 1.763-12.047; P = 0.002).

Conclusions: Pretreatment serum CRP levels could be an accurate biomarker of the survival of patients with advanced UC before GC therapy. Although this is a preliminary study with a small sample size, these results seem to be very useful in clinical practice and our findings should be confirmed in a larger group of patients.

No MeSH data available.


Related in: MedlinePlus

Kaplan-Meier analysis of cancer-specific survival in patients with advanced UC stratified by levels of CRP before GC therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3921783&req=5

Figure 0001: Kaplan-Meier analysis of cancer-specific survival in patients with advanced UC stratified by levels of CRP before GC therapy.

Mentions: Figure 1 shows a significantly worse CSS in the group with high CRP than with low CRP (P = 0.001). Among the other factors, low albumin (P = 0.008), low hemoglobin (P = 0.025), and pain (P = 0.002) were associated with poorer CSS rates (Table 3). Survival rates did not significantly differ between patients given either cisplatin or carboplatin. Multivariate analysis of factors before GC therapy showed that serum CRP was an independent significant predictor for CSS, with a hazard ratio of 4.608 (95% CI, 1.763-12.047; P = 0.002).


Serum C-reactive protein level is a significant prognostic indicator in patients with advanced urothelial cancer treated with gemcitabine-cisplatin or carboplatin - preliminary results.

Morizane S, Iwamoto H, Yao A, Isoyama T, Sejima T, Takenaka A - Cent European J Urol (2012)

Kaplan-Meier analysis of cancer-specific survival in patients with advanced UC stratified by levels of CRP before GC therapy.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3921783&req=5

Figure 0001: Kaplan-Meier analysis of cancer-specific survival in patients with advanced UC stratified by levels of CRP before GC therapy.
Mentions: Figure 1 shows a significantly worse CSS in the group with high CRP than with low CRP (P = 0.001). Among the other factors, low albumin (P = 0.008), low hemoglobin (P = 0.025), and pain (P = 0.002) were associated with poorer CSS rates (Table 3). Survival rates did not significantly differ between patients given either cisplatin or carboplatin. Multivariate analysis of factors before GC therapy showed that serum CRP was an independent significant predictor for CSS, with a hazard ratio of 4.608 (95% CI, 1.763-12.047; P = 0.002).

Bottom Line: The survival rates of patients with low serum albumin (<3.5 g/dL; P = 0.008), low hemoglobin (<10.1 mg/dL; P = 0.025), high CRP (>1.0 mg/dL; P = 0.001), and a positive pain score (P = 0.002) were significantly worse than those with better blood values and pain scores.Pretreatment serum CRP levels could be an accurate biomarker of the survival of patients with advanced UC before GC therapy.Although this is a preliminary study with a small sample size, these results seem to be very useful in clinical practice and our findings should be confirmed in a larger group of patients.

View Article: PubMed Central - PubMed

Affiliation: Division of Urology, Department of Surgery, Tottori University Faculty of Medicine, Tottori, Japan.

ABSTRACT

Introduction: This study determines prognostic factors in patients with advanced urothelial cancer (UC) treated with gemcitabine-cisplatin or carboplatin (GC).

Material and methods: The clinical records of 30 patients with advanced UC treated with GC were retrospectively reviewed. Twenty-six patients (86.7%) had previously undergone other chemotherapies. Hematological parameters such as: neutrophil, lymphocyte and platelet counts; hemoglobin, C-reactive protein (CRP), and albumin levels; pain score; primary tumor site; tumor grade; type of platinum anti-cancer drug; and performance status before treatment were evaluated. Survival rates were calculated using the Kaplan-Meier method and analyzed using the log-rank test. Multivariate analysis was performed using a Cox proportional hazards model.

Results: The median cancer-specific survival (CSS) was 12.5 months. The overall response rate (ORR) was 30.0%. The survival rates of patients with low serum albumin (<3.5 g/dL; P = 0.008), low hemoglobin (<10.1 mg/dL; P = 0.025), high CRP (>1.0 mg/dL; P = 0.001), and a positive pain score (P = 0.002) were significantly worse than those with better blood values and pain scores. Multivariate analysis revealed serum CRP level as an independent prognostic indicator with a hazard ratio of 4.608 (95% confidence interval (CI) of 1.763-12.047; P = 0.002).

Conclusions: Pretreatment serum CRP levels could be an accurate biomarker of the survival of patients with advanced UC before GC therapy. Although this is a preliminary study with a small sample size, these results seem to be very useful in clinical practice and our findings should be confirmed in a larger group of patients.

No MeSH data available.


Related in: MedlinePlus